drugset
drugset / Trial / NCT05684653

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

NCT05684653 ↗

Phase 1 Unknown 34 enrolled Beijing InnoCare Pharma Tech Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

This is an Open-Label, Parallel, Single-dose, Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of Orelabrutinib Tablets in Subjects with Varying Degrees of Hepatic Impairment

Timeline

Start
2023-03-17
Primary completion
2023-12-30
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Orelabrutinib Small molecule 50 mg Oral

Indications

No indication recorded.